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Where found: Widely distributed in the 
northeastern and upper midwestern 
United States.
Transmits: Lyme disease, anaplasmosis, 
babesiosis, and Powassan disease.
Comments: The greatest risk of being 
bitten exists in the spring, summer, 
and fall. However, adults may be out 
searching for a host any time winter 
temperatures are above freezing. Stages 
most likely to bite humans are nymphs 
and adult females.
LONE STAR TICK 
Amblyomma americanum
Where found: Widely distributed in the 
southeastern and eastern United States.
Transmits: Ehrlichia chaffeensis and 
Ehrlichia ewingii (which cause human 
ehrlichiosis), tularemia, and STARI. 
Comments: A very aggressive tick that bites 
humans. The adult female is distinguished by 
a white dot or “lone star” on her back. Lone 
star tick saliva can be irritating; redness and 
discomfort at a bite site does not necessarily 
indicate an infection. The nymph and adult 
females most frequently bite humans and 
transmit disease.
AMERICAN DOG TICK 
Dermacentor variabilis
Where found: Widely distributed east 
of the Rocky Mountains. Also occurs in 
limited areas on the Pacific Coast.
Transmits: Tularemia and Rocky 
Mountain spotted fever. 
Comments: The highest risk of being 
bitten occurs during spring and 
summer. Dog ticks are sometimes 
called wood ticks. Adult females are 
most likely to bite humans.
Engorged female Ixodes scapularis tick. 
Color may vary.

















BROWN DOG TICK  
Rhipicephalus sanguineus
Where found: Worldwide. 
Transmits: Rocky Mountain spotted 
fever (in the southwestern U.S. and along 
the U.S.-Mexico border). 
Comments: Dogs are the primary host 
for the brown dog tick in each of its 
life stages, but the tick may also bite 















GROUNDHOG TICK  
Ixodes cookei
Where found: Throughout the eastern 
half of the U.S. and Canada. 
Transmits: Powassan disease. 
Comments: Also called woodchuck ticks. 
All life stages feed on a variety of warm-
blooded animals, including groundhogs, 
skunks, squirrels, raccoons, foxes, 
weasels, and occasionally people and 
domestic animals. 
GULF COAST TICK  
Amblyomma maculatum
Where found: Coastal areas of the U.S. 
along the Atlantic coast and the Gulf of 
Mexico. 
Transmits: Rickettsia parkeri rickettsiosis, 
a form of spotted fever.
Comments: Larvae and nymphs feed 
on birds and small rodents, while adult 
ticks feed on deer and other wildlife. 
Adult ticks have been associated with 
transmission of R. parkeri to humans.
ROCKY MOUNTAIN  
WOOD TICK 
Dermacentor andersoni
Where found: Rocky Mountain states 
and southwestern Canada from 
elevations of 4,000 to 10,500 feet. 
Transmits:  Rocky Mountain spotted 
fever, Colorado tick fever, and tularemia.
Comments: Adult ticks feed primarily 
on large mammals. Larvae and nymphs 
feed on small rodents. Adult ticks are 







































Where found: Throughout the western 
half of the U.S. and southwestern 
Canada. 
Transmits: Tick-borne relapsing  
fever (Borrelia hermsii, B. parkerii, or  
B. turicatae)
Comments: Humans typically come 
into contact with soft ticks when they 
sleep in rodent infested cabins. The ticks 
emerge at night and feed briefly while 
the person is sleeping. The bites are 
painless, and most people are unaware 
that they have been bitten.
WESTERN BLACKLEGGED TICK  
Ixodes pacificus
Where found: Along the Pacific coast of 
the U.S., particularly northern California. 
Transmits: Anaplasmosis and Lyme 
disease. 
Comments: Nymphs often feed on 
lizards, as well as other small animals. As 
a result, rates of infection are usually low 
(~1%) in adults. Stages most likely to bite 















Overview of Tickborne Diseases





NOTE:  Each dot represents one case. Cases are reported from the infected person’s county of residence, not necessarily the 
place where they were infected.
NOTE:  During 2015, babesiosis was reportable in Alabama, Arkansas, California, Connecticut, Delaware, Illinois, Indiana, 
Louisiana, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Montana, Nebraska, New Hampshire, 
New Jersey, New York, North Dakota, Ohio, Oregon, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, 
Utah, Vermont, Washington, West Virginia, Wisconsin, and Wyoming.
NOTE:  In 2015, no cases of tickborne illness were reported from Hawaii. In 2015, Alaska reported 1 travel-related cases of Lyme 
















Anaplasmosis is most frequently reported from the upper midwest and northeastern U.S. in areas that 
correspond with the known geographic distribution of Lyme disease. 
INCUBATION PERIOD: 1–2 weeks
SIGNS AND SYMPTOMS




• Gastrointestinal symptoms (nausea, vomiting,  
diarrhea, anorexia)
• Cough
• Rash (rare cases)
The Signs and Symptoms list presents symptoms commonly seen 
with anaplasmosis. However, it is important to note that few people 
will develop all symptoms and the number and combination of 
symptoms varies greatly from person to person.
Anaplasmosis and ehrlichiosis have similar clinical 
presentations, but they are transmitted by two different 
species of ticks and generally occur in different regions of 
the U.S.
Anaplasmosis was formerly known as Human Granulocytic 
Ehrlichiosis (HGE).
Confirmation of the diagnosis is based on laboratory testing, but antibiotic therapy should not be delayed in a 
patient with a suggestive clinical presentation. 
GENERAL LABORATORY FINDINGS 
Typically Observed During the First Week of Clinical Disease:
• Mild anemia
• Thrombocytopenia
• Leukopenia (characterized by relative and absolute lymphopenia 
and a left shift) 
• Mild to moderate elevations in hepatic transaminases may occur in 
some patients.
• Visualization of morulae in the cytoplasm of granulocytes during 
examination of blood smears is highly suggestive of a diagnosis; 
however, blood smear examination is insensitive and should never 
be relied upon solely to rule anaplasmosis in or out.
LABORATORY CONFIRMATION 
• Detection of DNA by PCR of whole blood. This method is most 
sensitive during the first week of illness; sensitivity may decrease 
after administration of antibiotics. 
• Demonstration of a four-fold change in IgG-specific antibody 
titer by indirect immunofluorescence antibody (IFA) assay 
in paired serum samples. Antibodies to A. phagocytophilum 
are usually detectable within 7–10 days after illness onset. The 
reference standard serologic test looks for a four-fold change in 
antibody titers using IFA on paired samples. The first sample should 
be taken within the first week of illness and the second should be 
taken 2 to 4 weeks later. 
NOTE: IgM antibodies are less specific than IgG antibodies 
and are more likely to generate false positives. IgM 
results alone should not be used for laboratory 
diagnosis.
NOTE: Consider the possibility of coinfection with Babesia 
microti and/or Borrelia burgdorferi.
NOTE: Antibody titers are frequently negative in the first 
7–10 days of illness, thus serologic tests may be 















Anaplasmosis, ehrlichiosis, and Rocky Mountain spotted fever are treated in the same manner with doxycycline. Clinical suspicion of 
any of these diseases is sufficient to begin treatment. Delay in treatment may result in severe illness and even death. The regimens 
listed below are guidelines only and may need to be adjusted depending on a patient’s age, medical history, underlying health 
conditions, pregnancy status, or allergies. Consult an infectious disease specialist in cases of documented pregnancy or life-
threatening allergies to doxycycline.
AGE CATEGORY DRUG DOSAGE MAXIMUM DURATION (DAYS)
Adults Doxycycline 100 mg twice per day, orally or IV 100 mg/dose Patients with suspected anaplasmosis 
infection should be treated with 
doxycycline for 10-14 days to provide 
appropriate length of therapy for 
possible incubating co-infection with 
Lyme diseaseChildren weighing 
<100 lbs. (45.4 kg)
Doxycycline
2.2 mg/kg per dose twice per  
day, orally or IV
100 mg/dose 
NOTE: Use doxycycline as first-line treatment for suspected anaplasmosis in patients of all ages. The use of 
doxycycline to treat suspected anaplasmosis in children is recommended by both the CDC and the 
American Academy of Pediatrics Committee on Infectious Diseases. Use of antibiotics other than 
doxycycline increases the risk of patient death. At the recommended dose and duration needed to treat 
anaplasmosis, no evidence has been shown to cause staining of permanent teeth, even when five courses 
are given before the age of eight. 
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and other Babesia species
WHERE FOUND
Babesiosis is most frequently reported from the 
northeastern and upper midwestern United States 
in areas where Babesia microti is endemic. Sporadic 
cases of infection caused by novel Babesia agents have 
been detected in other U.S. regions, including the 
West Coast. In addition, transfusion-associated cases of 
babesiosis can occur anywhere in the country.
INCUBATION PERIOD: 1–9+ weeks
SIGNS AND SYMPTOMS
• Fever, chills, sweats
• Malaise, fatigue
• Myalgia, arthralgia, headache
• Gastrointestinal symptoms, such as 
anorexia and nausea (less common: 
abdominal pain, vomiting)
• Dark urine
• Less common: cough, sore throat, 
emotional lability, depression, 
photophobia, conjunctival injection
• Mild splenomegaly, mild 
hepatomegaly, or jaundice may occur 
in some patients
NOTE: Not all infected persons are symptomatic or febrile. The clinical manifestations, 
if any, usually develop within several weeks after the exposure but may develop 
or recur months later (for example, in the context of surgical splenectomy).
Babesiosis is caused by parasites that 
infect red blood cells. Most U.S. cases 
are caused by Babesia microti, which is 
transmitted by Ixodes scapularis ticks, 
primarily in the Northeast and upper 
Midwest. Babesia parasites also can be 
transmitted via transfusion, anywhere, 
at any time of the year. As of February 
2017, no Babesia tests have been licensed 
for screening blood donors. Congenital 
transmission also has been reported.
Babesia infection can range from 
asymptomatic to life threatening. 
Risk factors for severe babesiosis 
include asplenia, advanced age, and 
impaired immune function. Severe 
cases can be associated with marked 
thrombocytopenia, disseminated 
intravascular coagulation, hemodynamic 
instability, acute respiratory distress, 
renal failure, hepatic compromise, altered 
mental status, and death.
GENERAL LABORATORY FINDINGS 
• Decreased hematocrit due to hemolytic anemia
• Thrombocytopenia
• Elevated serum creatinine and blood urea nitrogen  
(BUN) values
• Mildly elevated hepatic transaminase values
LABORATORY DIAGNOSIS 
• Identification of intraerythrocytic Babesia parasites by light-
microscopic examination of a peripheral blood smear; or
• Positive Babesia (or B. microti) polymerase chain reaction 
(PCR) analysis; or
• Isolation of Babesia parasites from a whole blood specimen 
by animal inoculation (in a reference laboratory).
SUPPORTIVE LABORATORY CRITERIA 
• Demonstration of a Babesia-specific antibody titer 
by indirect fluorescent antibody (IFA) testing for total 
immunoglobulin (Ig) or IgG.
NOTE: If the diagnosis of babesiosis is being considered, manual 
(nonautomated) review of blood smears should be 
requested explicitly. In symptomatic patients with acute 
infection, Babesia parasites typically can be detected by 
blood-smear examination, although multiple smears 
may need to be examined. Sometimes it can be difficult 
to distinguish between Babesia and malaria parasites 
and even between parasites and artifacts (such as 
stain or platelet debris). Consider having a reference 
laboratory confirm the diagnosis and the species. In 
some settings, molecular techniques can be useful for 
detecting and differentiating among Babesia species.
NOTE: Antibody detection by serologic testing can provide 
supportive evidence for the diagnosis but does not 

















and other Babesia species
Treatment decisions and regimens should consider the patient’s age, clinical status, immunocompetence, splenic function, 
comorbidities, pregnancy status, other medications, and allergies. Expert consultation is recommended for persons who have or are 
at risk for severe or relapsing infection or who are at either extreme of age.
For ill patients, babesiosis usually is treated for at least 7–10 days with a combination of two medications—typically, either 
atovaquone PLUS azithromycin; OR clindamycin PLUS quinine (this combination is the standard of care for severely ill patients).  









Atovaquone 750 mg orally every 12 hours N/A 7–10
Azithromycin
On the first day, give a total dose in the range of 
500–1000 mg orally; on subsequent days, give a 
total daily dose in the range of 250–1000 mg*





300–600 mg IV every 6 hours OR 600 mg orally 
every 8 hours**
N/A 7–10
Quinine** 650 mg orally every 6–8 hours N/A 7–10
* The upper end of the range (600–1000 mg per day) has been used for adults who are immunocompromised.
** The standard of care for patients with severe babesiosis (e.g., with parasitemia levels ≥10% and/or organ-system dysfunction) is quinine plus 
clindamycin; typically, the clindamycin is administered intravenously. Such patients also might require or benefit from exchange transfusions, 
vasopressor therapy, mechanical ventilation, or dialysis.
NOTE: Most persons without clinical manifestations of infection do not require treatment. However, consider treating persons who have 
had demonstrable parasitemia for more than 3 months.
REFERENCES
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anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089–
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Ehrlichia chaffeensis, Ehrlichia ewingii, 
Ehrlichia muris-like (EML)
WHERE FOUND
Ehrlichiosis is most frequently reported from the southeastern and south-central U.S., from the eastern 
seaboard extending westward to Texas. The areas from which cases are reported correspond with the 
known geographic distribution of the lone star tick (Amblyomma americanum), which is associated with 
transmission of both E. chaffeensis and E. ewingii. Three states (Oklahoma, Missouri, Arkansas) account for 
35% of all reported E. chaffeensis infections. Since 2009,  >70 cases of ehrlichiosis caused by Ehrlichia muris 
eauclarensis, have been identified in patients in the upper Midwest. The tick responsible for transmitting 
this new subspecies is suspected to be Ixodes scapularis and the clinical presentation is generally similar to 
those associated with infections caused by E. chaffeensis and E. ewingii. No deaths have been reported.






• Muscle pain 
• Gastrointestinal symptoms (nausea, vomiting,  
diarrhea, anorexia) 
• Confusion 
• Conjunctival injection 
• Rash (more commonly reported among children)
The Signs and Symptoms list presents symptoms commonly seen 
with ehrlichiosis. However, it is important to note that few people 
will develop all symptoms and the number and combination of 
symptoms varies greatly from person to person.
Ehrlichiosis and anaplasmosis have a similar clinical 
presentation, but they are transmitted by two different 
species of ticks and generally occur in different regions 
of the U.S. 
Confirmation of the diagnosis is based on laboratory testing, but antibiotic therapy should not be delayed in a 
patient with a suggestive clinical presentation.
GENERAL LABORATORY FINDINGS
Typically observed during the first week of clinical disease:
• Thrombocytopenia
• Leukopenia (absolute)
• Anemia (generally occurs later in illness than 
thrombocytopenia or leukopenia )
• Mild to moderate elevations in hepatic transaminases 
• During the acute stage of illness, morulae can be detected  
in about 20% of patients. E. chaffeensis most commonly  
infects monocytes, whereas E. ewingii more commonly  
infects granulocytes.
LABORATORY CONFIRMATION
• Detection of DNA by PCR of whole blood. This method is 
most sensitive during the first week of illness and sensitivity 
can decrease after administration of tetracycline-class 
antibiotics.
• Demonstration of a four-fold change in IgG-specific 
antibody titer by indirect immunofluorescence antibody 
(IFA) assay in paired serum samples. Antibodies to Ehrlichia 
sp. are usually detectable within 7–10 days after illness onset. 
The reference standard serologic test looks for a four-fold 
change in antibody titers using IFA on paired samples. The first 
sample should be taken within the first week of illness and the 
second should be taken 2 to 4 weeks later.
NOTE: IgM antibodies are less specific than IgG antibodies and 
are more likely to generate false positive results. IgM results 
alone should not be used for laboratory diagnosis.
NOTE: Antibody titers are frequently negative in the first 7–10 
days of illness, thus serologic tests may be falsely negative 
















Ehrlichia chaffeensis, Ehrlichia ewingii, 
Ehrlichia muris-like (EML)
Anaplasmosis, ehrlichiosis, and Rocky Mountain spotted fever are treated in the same manner with doxycycline. Clinical suspicion of 
any of these diseases is sufficient to begin treatment. Delay in treatment may result in severe illness and death. The regimens listed 
below are guidelines only and may need to be adjusted depending on a patient’s age, medical history, underlying health conditions, 
pregnancy status, or allergies. Consult an infectious disease specialist in cases of documented pregnancy or life-threatening allergies 
to doxycycline.
AGE CATEGORY DRUG DOSAGE MAXIMUM DURATION (DAYS)
Adults Doxycycline 100 mg twice per day, orally or IV 100 mg/dose
Patients should be treated for at 
least 3 days after the fever subsides 
and until there is evidence of clinical 
improvement. Minimum course of 
treatment is 5–7 days.Children weighing 
<100 lbs. (45.4 kg)
Doxycycline
2.2 mg/kg per dose twice per day, 
orally or IV
100 mg/dose
NOTE: Use doxycycline as first-line treatment for suspected ehrlichiosis in patients of all ages. The use of doxycycline 
to treat suspected ehrlichiosis in children is recommended by both the CDC and the American Academy of 
Pediatrics Committee on Infectious Diseases. Use of antibiotics other than doxycycline increases the risk of 
patient death. At the recommended dose and duration needed to treat ehrlichiosis, no evidence has been 
shown to cause staining of permanent teeth, even when five courses are given before the age of eight. 
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Society of Tropical Medicine and Hygiene 63rd Annual Meeting, New Orleans, LA. November 2013.
Todd SR, Dahlgren FS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted 













Lyme Disease AGENTBorrelia burgdorferi
WHERE FOUND
Lyme disease is most frequently reported from the upper midwestern 
and northeastern U.S. Some cases are also reported in northern California, 
Oregon, and Washington. In 2013, 95% of Lyme disease cases were reported 
from 14 states: Connecticut, Delaware, Maine, Maryland, Massachusetts, 
Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Rhode 
Island, Vermont, Virginia, and Wisconsin.
INCUBATION PERIOD: 3–30 days
SIGNS AND SYMPTOMS
Localized Stage†
• Erythema migrans (EM)—red ring-like or 
homogenous expanding rash; classic rash 
not present in all cases. See examples on 
following pages.
• Flu-like symptoms – malaise, headache, 
fever, myalgia, arthralgia
• Lymphadenopathy 
†During the localized (early) stage of illness, 
Lyme disease may be diagnosed clinically in 
patients who present with an EM rash. Serologic 
tests may be insensitive at this stage. During 
disseminated disease, however, serologic tests 
are usually positive.  
Disseminated Stage




• Transient, migratory arthritis and effusion 
in one or multiple joints
• Migratory pain in tendons, bursae, muscle, 
and bones
• Baker’s cyst
• If untreated, arthritis may recur in same or 
different joints
Cardiac Manifestations




• Bell’s palsy or other cranial neuropathy
• Meningitis
• Motor and sensory radiculoneuropathy, 
mononeuritis multiplex
• Subtle cognitive difficulties 
• Encephalitis, encephalomyelitis, subtle 
encephalopathy, pseudotumor cerebri  
(all rare)
Additional Manifestations




• Elevated erythrocyte sedimentation rate  
• Mildly elevated hepatic transaminases
• Microscopic hematuria or proteinuria
• In Lyme meningitis, CSF typically shows 
lymphocytic pleocytosis, slightly elevated 
protein, and normal glucose.
LABORATORY DIAGNOSIS 
• Demonstration of diagnostic IgM or IgG 
antibodies in serum. A two-tier testing 
protocol is recommended—EIA or IFA 
should be performed first; if positive or 
equivocal it is followed by a Western blot.
• Isolation of organism from a clinical 
specimen.
• In suspected Lyme meningitis, testing  
for intrathecal IgM or IgG antibodies may  
be helpful.
NOTES ON SEROLOGIC TESTS FOR  
LYME DISEASE 
• Serologic tests are insensitive during the  
first few weeks of infection. During this 
stage, patients with an EM rash may be 
diagnosed clinically.  While not necessary, 
acute and convalescent titers may be helpful 
in some cases.
• In persons with illness > 1 month, only IgG 
testing should be performed (not IgM).   
A positive IgM test alone is not sufficient to 
diagnose current disease.
• Due to antibody persistence, single positive 
serologic test results cannot distinguish 
between active and past infection.
• Serologic tests cannot be used to measure 
treatment response.
• Enzyme immunoassay (EIA) and 
immunofluorescence assay (IFA) tests have 
low specificity and may yield false-positive 
results. They may cross-react with antibodies 
to commensal or pathogenic spirochetes, 
some viral infections (e.g., varicella, Epstein-
Barr virus), or certain autoimmune diseases 
(e.g., lupus).
LYME DISEASE OR STARI?
An erythema migrans-like rash has also 
been described in humans following 
bites of the lone star tick, Amblyomma 
americanum. This condition has been 
named Southern Tick-Associated Rash 
Illness (STARI). Although the rash may 
be accompanied by flu-like symptoms, 
long-term sequelae have not been 
reported. Because the cause of STARI  
is unknown, diagnostic blood tests are 
not available.
Lone star ticks can be found from central 
Texas and Oklahoma eastward across 
the southern states and along the 
Atlantic coast as far north as Maine.
It is not known whether antibiotic 
treatment is necessary or beneficial 
for patients with STARI. Nevertheless, 
because STARI resembles early Lyme 
disease, physicians often treat patients 
with the same antibiotics recommended 
for Lyme disease.
NOTE: Coinfection with B. microti and/or A. phagocytophilum should be considered in patients who present with initial symptoms that are more 
severe than are commonly observed with Lyme disease alone, especially in those who have high-grade fever for more than 48 hours despite 
appropriate antibiotic therapy or who have unexplained leukopenia, thrombocytopenia, or anemia. Coinfection might also be considered in 












Lyme Disease AGENTBorrelia burgdorferi
Treatment regimens listed in the following table are for localized (early) Lyme disease. Treatment guidelines for patients with 
disseminated (late) Lyme disease are outlined in the reference below.†
These regimens are guidelines only and may need to be adjusted depending on a patient’s age, medical history, underlying health 
conditions, pregnancy status or allergies. Consult an infectious disease specialist for the most current treatment guidelines or for 
individual patient treatment decisions. 




Doxycycline 100 mg, twice per day orally N/A 14 (14–21)
Cefuroxime axetil 500 mg, twice per day orally N/A 14 (14–21)
Amoxicillin 500 mg, three times per day orally N/A 14 (14–21)
Children
Amoxicillin 50 mg/kg per day orally, divided into 3 doses 500 mg per dose 14 (14–21)
Doxycycline 4 mg/kg per day orally, divided into 2 doses 100 mg per dose 14 (14–21)
Cefuroxime axetil 30 mg/kg per day orally, divided into 2 doses 500 mg per dose 14 (14–21)
NOTE: For patients intolerant of amoxicillin, doxycycline, and cefuroxime axetil, the macrolides azithromycin, clarithromycin, or 
erythromycin may be used, although they have a lower efficacy. Patients treated with macrolides should be closely observed 
to ensure resolution of clinical manifestations. 
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†Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment and prevention of Lyme disease, human granulocytic 















Lyme Disease AGENTBorrelia burgdorferi
The erythema migrans (EM) rash occurs in 70–80% of patients with Lyme disease. EM rashes expand slowly over a few days after 
which they may develop a “bull’s-eye” appearance consisting of a red ring with central clearing. However, EM may take alternate 
forms—solid lesions, blue-purple hues, and crusted or blistering lesions have all been documented. The rash is not painful or pruritic, 
but it may be warm to the touch. If early localized Lyme disease is not treated, patients may develop multiple secondary circular 














Classic EM—Circular red rash with 





























































Red-blue lesion with central clearing 















Early disseminated Lyme disease—
multiple red lesions with dusky centers
Tick bite with mild allergic reaction. Not an 
erythema migrans. Allergic reactions typically 
appear within the first 48 hours of tick attachment 
and are usually <5 cm in diameter.
















Although Rocky Mountain spotted fever cases have been reported throughout most of the contiguous 
U.S., five states (North Carolina, Oklahoma, Arkansas, Tennessee, and Missouri) account for over 60% of 
RMSF cases.
Rocky Mountain spotted fever has become increasingly common in certain areas of Arizona over the 
last several years. Between 2003 and 2012 over 250 cases and 19 fatalities occurred. RMSF can be rapidly 
fatal if not treated within the first 5 days of symptoms. Before tetracycline antibiotics were available, 
case fatality rates ranged from 20–80%.
INCUBATION PERIOD: 2–14 days
SIGNS AND SYMPTOMS
• Fever, chills 
• Severe headache 
• Malaise
• Myalgia
• Gastrointestinal symptoms (nausea, 
vomiting, anorexia, abdominal pain, 
diarrhea, abdominal tenderness) 
• Photophobia
• Focal neurologic deficits, including 
cranial or peripheral motor nerve 
paralysis or sudden transient deafness 
Maculopapular Rash
• Typically appears 2–5 days after the 
onset of fever
• Small, flat, pink, non-itchy spots 
(macules) initially appear on the wrists, 
forearms, and ankles then spread to the 
trunk and sometimes palms and soles. 
• Rash may not develop until late in the 
disease process, after treatment should 
have already begun. Approximately 
10% of RMSF patients never develop a 
rash at all.
• Consider RMSF if other signs and 
symptoms support a diagnosis, even if a 
rash is not present. 
Petechial Rash
• Red to purple spots (petechiae) are 
usually not seen until day 6 or later after 
onset of symptoms.
• Petechial rash is considered a sign of 
progression to severe disease. Every 
attempt should be made to begin 
treatment before petechiae develop. 
NOTE: Neurologic symptoms are typically not seen until later in the disease progression and may be prevented with early treatment.
Confirmation of the diagnosis is based on laboratory testing, 
but antibiotic therapy should not be delayed in a patient with 
a suggestive clinical presentation. Antibiotics are less likely to 
prevent fatal outcome from RMSF if started after day 5 of symptoms.
GENERAL LABORATORY FINDINGS
• Thrombocytopenia
• Mildly elevated hepatic transaminase levels
• Hyponatremia
LABORATORY CONFIRMATION 
• Demonstration of a four-fold change in IgG-specific antibody titer by indirect 
immunofluorescence antibody (IFA) assay in paired serum samples. Antibodies 
to R rickettsii are usually detectable within 7–10 days after illness onset. The reference 
standard serologic test looks for a four-fold change in antibody titers using IFA on 
paired samples. The first sample should be taken within the first week of illness and 
the second should be taken 2 to 4 weeks later. 
• Detection of DNA in a skin biopsy specimen of a rash lesion by polymerase chain 
reaction (PCR) assay or in an acute phase whole blood specimen, although this 
sample can be less sensitive.
• Immunohistochemical (IHC) staining of organism from skin or tissue biopsy 
specimen.
NOTE: IgM antibodies are less specific than IgG antibodies and are more likely to generate 
false positives. IgM results alone should not be used for laboratory diagnosis.
NOTE: Antibody titers are frequently negative in the first 7–10 days of illness, thus 
serologic tests may be falsely negative during this time period.
Rocky Mountain Spotted 
Fever or Rickettsia parkeri 
rickettsiosis?
Rickettsia rickettsii and R. parkeri cause 
febrile illnesses that can be difficult to 
diagnosis in the early stages of infection. 
RMSF is most often transmitted by 
American dog ticks in the eastern, 
central and Pacific costal U.S., by Rocky 
Mountain wood ticks in the Rocky 
Mountain states, and by brown dog ticks 
in the southwestern U.S. and Mexico. 
RMSF is a rapidly progressive illness 
which can be fatal if untreated. 
Rickettsia parkeri rickettsiosis is 
transmitted by Gulf Coast ticks in the 
southeastern and mid-Atlantic states  
as well as parts of southern Arizona.  
R. parkeri rickettsiosis is characteristically 
less severe than RMSF and almost 
always associated with an inoculation 
eschar at the site of tick attachment. 
















Anaplasmosis, ehrlichiosis, and Rocky Mountain spotted fever are treated in the same manner with doxycycline.† Clinical suspicion 
of any of these diseases is sufficient to begin treatment. Delay in treatment may result in severe illness and even death. The regimens 
listed below are guidelines only and may need to be adjusted depending on a patient’s age, medical history, underlying health 
conditions, pregnancy status, or allergies. Consult an infectious disease specialist in cases of pregnancy or documented life-
threatening allergies to doxycycline.
AGE CATEGORY DRUG DOSAGE MAXIMUM DURATION (DAYS)
Adults Doxycycline 100 mg twice per day, orally or IV 100 mg/dose
Patients should be treated for at 
least 3 days after the fever subsides 
and until there is evidence of clinical 
improvement. Minimum course of 
treatment is 5–7 days.Children weighing 
<100 lbs. (45.4 kg)
Doxycycline
2.2 mg/kg per dose twice per day, 
orally or IV
100 mg/dose
NOTE: Use doxycycline as the first-line treatment for suspected RMSF in patients of all ages. The use of doxycycline 
to treat suspected RMSF in children is recommended by both the CDC and the American Academy of Pediatrics 
Committee on Infectious Diseases. Use of antibiotics other than doxycycline increases the risk of patient 
death. At the recommended dose and duration needed to treat RMSF, no evidence has been shown to cause 
staining of permanent teeth, even when five courses are given before the age of eight. 
REFERENCES 
†Centers for Disease Control and Prevention. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted 
fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis—United States: a practical guide for health care  
and public health professionals. MMWR 2016; 65 (No.RR-2). 
Smithee L, et al. Public health reporting and national notification for spotted fever rickettsiosis (including Rocky Mountain spotted 
fever). Council of State and Territorial Epidemiologists, Infectious Diseases Committee, 2009 Position Statement.  
http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/PS/09-ID-16.pdf
Todd SR, Dahlgren FS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted 
fever. J Pediatr, Available online 17 March 2015, ISSN 0022-3476, http://dx.doi.org/10.1016/j.jpeds.2015.02.015
Walker DH, Raoult D. Rickettsia ricketsii and other spotted fever group rickettsiae (Rocky Mountain spotted fever and other spotted 
fevers). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases.  










In the U.S., naturally occurring tularemia infections have been reported from all states except Hawaii. 
Ticks that transmit tularemia to humans include the dog tick (Dermacentor variabilis), the wood tick 
(Dermacentor andersoni), and the lone star tick (Amblyomma americanum). Other transmission routes 
include inhalation and direct inoculation.



















• Preauricular, submandibular and  
cervical lymphadenopathy
Oropharyngeal 
• Severe throat pain





• Pleuritic chest pain
• Hilar adenopathy, infiltrate, or pleural 
effusion may be present on chest X-ray
Typhoidal 
• Characterized by any combination of the 
general symptoms (without localizing 
symptoms of other syndromes)
NOTE:  The clinical presentation of tularemia will depend on a number of factors, 
including the portal of entry. 
GENERAL LABORATORY FINDINGS 




• Elevated hepatic transaminases




• Demonstration of a four-fold change in antibody titer in 
paired sera; or
• Isolation of organism from a clinical specimen; or
• Detection of organism by immunofluorescence assay (IFA) 
test or a single elevated serum antibody titer is supportive 
of the diagnosis; however, a single antibody titer should be 









The regimens listed below are guidelines only and may need to be adjusted depending on a patient’s age, medical history, 
underlying health conditions, pregnancy status or allergies. Consult an infectious disease specialist for the most current treatment 
guidelines or for individual patient treatment decisions.




Streptomycin 1 g IM twice daily 2 g per day Minimum 10
Gentamicin*
5 mg/kg IM or IV daily (with desired peak 
serum levels of at least 5 mcg/mL)
Monitor serum drug levels Minimum 10
Ciprofloxacin* 400 mg IV or PO twice daily N/A 10–14
Doxycycline 100 mg IV or PO twice daily N/A 14–21
Children
Streptomycin 15 mg/kg IM twice daily 2 g per day Minimum 10
Gentamicin* 2.5 mg/kg IM or IV 3 times daily
Monitor serum drug levels and consult a 
pediatric infectious disease specialist
Minimum 10
Ciprofloxacin* 15 mg/kg IV or PO twice daily 1 g per day 10
*Not a U.S. FDA-approved use, but has been used successfully to treat patients with tularemia.
NOTE: Gentamicin or streptomycin is preferred for treatment of severe tularemia. Doses of both streptomycin and gentamicin should be 
adjusted for renal insufficiency.
NOTE: Chloramphenicol may be added to streptomycin to treat meningitis.
REFERENCES
Centers for Disease Control and Prevention. Tularemia—United States, 2001-2010. MMWR 62(47):963–966.
Dennis D, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001. 
285(21): 2763–2773. 
Feldman KA, Enscore RE, Lathrop SL, et al. An outbreak of primary pneumonic tularemia on Martha’s Vineyard. NEJM 2001; 345: 
1601–1606. 
Johansson A, Berglund L, Sjöstedt A, Tärnvik. A ciprofloxacin for treatment of tularemia. Clin Infect Dis 2001;33:267–8. 
Penn RL. Francisella tularensis (Tularemia). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s Principles 
and Practice of Infectious Diseases. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005. p. 2674–2685.









Colorado Tick Fever (CTF) Agent: Colorado tick fever virus
WHERE FOUND The geographic range of Colorado tick fever virus includes the western United States and southwestern Canada at elevations 
4,000 to 10,000 feet. Cases occur primarily in Colorado, Utah, Montana, and Wyoming. Although rare, the virus can also be transmitted from 
person-to-person via blood transfusion.
INCUBATION PERIOD: 1–14 days
SIGNS AND SYMPTOMS
• Fever, chills, headache, myalgias, and 
lethargy
• ~50% of patients have a biphasic illness with 
symptoms remitting after 2 to 4 days, but 
then recurring 1 to 3 days later
• Conjunctival injection, pharyngeal erythema 
and lymphadenopathy may be present
• Maculopapular or petechial rash in <20%  
of patients
• Prolonged convalescence characterized by 
weakness and fatigue is common in adults
• Life-threatening complications and death 
are rare and usually associated with 






• Culture and RT-PCR during first 2 weeks  
of illness
• Serologic assays (e.g., IgM-capture 
EIA, indirect fluorescent antibody, and 
plaque-reduction neutralization) on 
convalescent samples. IgM antibodies 
usually do not appear until 14–21 days 
after illness onset.
TREATMENT
No specific antiviral treatment is available. 
Patients with suspected CTF should receive 
supportive care as appropriate. Patients 
with confirmed CTF should defer blood and 
bone marrow donation for at least 6 months 
after recovery.
REFERENCES
Brackney MM, Marfin AA, Staples JE, et al. Epidemiology 
of Colorado tick fever in Montana, Utah, and Wyoming, 
1995–2003. Vector Borne Zoonotic Dis 2010;10:381–385.
Centers for Disease Control and Prevention. West Nile Virus 
and Other Nationally Notifiable Arboviral Diseases—United 
States, 2015. MMWR 2017; 66(02);51-55. 
Fischer M, Tsai TF.  Coltiviruses (Colorado Tick Fever). In: 
Principles and Practice of Pediatric Infectious Diseases, 
3rd edition. Eds: Long SS, Pickering LK, Prober CG. Elsevier 
2008:1076–1078.
Goodpasture HC, Poland JD, Francy DB, Bowen GS, Horn KA. 
Colorado tick fever: clinical, epidemiologic, and laboratory 
aspects of 228 cases in Colorado in 1973–1974. Ann Intern 
Med 1978;88:303–310.
Lambert AJ, Kosoy O, Velez JO, Russell BJ, Lanciotti RS. 
Detection of Colorado Tick Fever viral RNA in acute human 
serum samples by a quantitative real-time RT-PCR assay. J 
Virol Methods 2007;140:43–48.
Romero JR, Simonsen KA. Powassan encephalitis and 
Colorado tick fever. Infect Dis Clin North Am 2008;22:545–559.
Spruance SL, Bailey A. Colorado Tick Fever. A review of  
115 laboratory confirmed cases. Arch Intern Med 
1973;131:288–293.
Tickborne Relapsing Fever (TBRF) Agent: Borrelia hermsii and other spp.
WHERE FOUND In the U.S., TBRF occurs most commonly in 14 western states: Arizona, California, Colorado, Idaho, Kansas, Montana, Nevada, 
New Mexico, Oklahoma, Oregon, Texas, Utah, Washington, and Wyoming. Most cases occur in the summer when people vacation and sleep 
in rodent-infested cabins. However, TBRF can also occur in the winter months when fires started to warm a cabin activate ticks resting in the 
walls and woodwork.
INCUBATION PERIOD: ~7 days, followed 
by recurring febrile episodes that last ~3 








COMMON FINDINGS ON ROUTINE 
LABORATORY TESTS
• Normal to increased white blood cell  
count with a left shift
• Mildly increased serum bilirubin
• Mild to moderate thrombocytopenia
• Elevated erthrocyte sedimentation rate
• Slightly prolonged prothrombin time 
(PT) and partial thromboplastin time 
(PTT)
LABORATORY DIAGNOSIS
• Observation of Borrelia spirochetes 
in smears of peripheral blood, bone 
marrow, or CSF
• Organisms are best detected in blood 
obtained while a person is febrile
• Serologic testing for TBRF is not 
standardized and results may vary by 
laboratory
TREATMENT
• Tetracycline 500 mg every 6 hours 
for 10 days is the preferred oral 
regimen for adults. If tetracyclines are 
contraindicated, an effective alternative 
is erythromycin 500 mg (or 12.5 mg/kg) 
every 6 hours for 10 days. 
• For CNS involvement, ceftriaxone 2 g per 
day for 10–14 days is preferred. 
• When initiating antibiotic therapy, all 
patients should be observed during the 
first 4 hours of treatment for a Jarisch-
Herxheimer reaction. 
• Acute respiratory distress syndrome 
requiring intubation has occurred in several 
patients undergoing TBRF treatment.
REFERENCES
Centers for Disease Control and Prevention. Acute 
respiratory distress syndrome in persons with tickborne 
relapsing fever—Three states, 2004–2005. MMWR 2007; 
56(41):1073–1076.
Dworkin MS, Schwan TG, et al. Tick-borne relapsing 
fever. Infect Dis Clin North Am 2008 Sep;22(3):449-–8.
Hayes E B and Dennis DT. Relapsing fever. In: Kasper DL, 
Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, 
eds. Harrison’s Principles of Internal Medicine. 16th ed. 








Powassan Disease Agent: Powassan virus
WHERE FOUND Powassan virus infections have been recognized in the United States, Canada and Russia. In the United States, cases 
have been reported primarily from northeastern states and the Great Lakes region.
INCUBATION PERIOD: 1 to 4 weeks
SIGNS AND SYMPTOMS
• Fever, headache, vomiting, and 
generalized weakness
• Usually progresses to meningo-
encephalitis. May include meningeal 
signs, altered mental status, seizures, 
aphasia, paresis, movement disorders,  
or cranial nerve palsies
GENERAL LABORATORY FINDINGS
• CSF findings include lymphocytic 
pleocytosis (neutrophils can 
predominate early), normal or mildly 
elevated protein, and normal glucose
LABORATORY DIAGNOSIS
• No commercially-available tests; testing 
available at CDC and selected state 
health departments.
• Measurement of virus-specific IgM 
antibodies in serum or cerebrospinal 
fluid (CSF). Cross-reaction with other 
flaviviruses (e.g., West Nile, dengue, 
or St. Louis viruses) can occur; 
plaque reduction neutralization tests 
should be performed to confirm the 
diagnosis.
• RT-PCR may detect viral RNA in 
acute CSF specimens or tissues but 
the sensitivity is unknown and this 
method should not be used to rule 
out the diagnosis.
TREATMENT
• No specific antiviral treatment 
for Powassan disease is available. 
Patients with suspected Powassan 
disease should receive supportive 
care as appropriate. 
REFERENCES
Centers for Disease Control and Prevention. West 
Nile Virus and Other Nationally Notifiable Arboviral 
Diseases—United States, 2015. MMWR 2017; 
66(02);51-55. 
Centers for Disease Control and Prevention. Outbreak 
of Powassan encephalitis—Maine and Vermont, 
1999–2001. MMWR 2001; 50(35):761–764. 
Ebel GD. Update on Powassan virus: emergence of 
a North American tick-borne flavivirus. Annu Rev 
Entomol 2010;55:95–110. 
Gholam BI, Puksa S, Provias JP. Powassan encephalitis: 
a case report with neuropathology and literature 
review. CMAJ 1999;161(11):1419–1422. 
Hinten SR, Beckett GA, Gensheimer KF, et al. Increased 
recognition of Powassan encephalitis in the United 
States, 1999–2005. Vector Borne Zoonotic Dis 
2008;8(6):733–740. 
Romero JR, Simonsen KA. Powassan encephalitis 
and Colorado tick fever. Infect Dis Clin North Am 
2008;22(3):545–559.
Tickborne Diseases Abroad
Activities that increase risk for tick exposure worldwide include (but are not limited to): outdoor recreation such as camping, hiking, 
fishing, or bicycling; military training; outdoor occupations such as forestry; and collecting mushrooms, berries, or flowers in forested 
or agricultural areas.
DISEASE & ETIOLOGIC AGENT(S) GEOGRAPHIC LOCATION AND ADDITIONAL RISK FACTORS
Lyme Disease
Borrelia afzelii, Borrelia garinii, B. burgdorferi sensu stricto 
Eastern and central Europe, northern Asia
Tick-Borne Encephalitis
Tick-borne encephalitis virus
Temperate regions of Europe and northern Asia. May also be acquired by ingestion of 
unpasteurized dairy products from infected goats, sheep, or cows.
Spotted Fever Group Rickettsioses 
(includes tick typhuses)
R. akari, R. parkeri, R. africae, R. japonica, R. felis, etc.
All continents except Antarctica. R. africae infection has been reported as a cause of fever in 
travelers returning from South Africa.
Crimean-Congo Hemorrhagic Fever
CCHF virus
Asia, Africa, and Europe. May also be acquired by contact with infected blood or saliva or inhalation 
of infected aerosols.
Omsk Hemorrhagic Fever
Omsk hemorrhagic fever virus
Southwestern Russia. May also be acquired by direct contact with infected muskrats.
Kyasanur Forest Disease
Kyasanur forest disease virus
Southern India, Saudi Arabia (aka Alkhurma disease in Saudi Arabia). Typically associated with 
exposure while harvesting forest products. 
NOTE: Anaplasmosis, babesiosis, ehrlichiosis, tularemia, TBRF, and Powassan disease can also be acquired internationally. Please see 
disease-specific references for more information on worldwide distribution.
REFERENCE




Ticks are generally found near the ground, in brushy or wooded areas. They can’t jump or fly. Instead, they climb tall grasses  
or shrubs and wait for a potential host to brush against them. When this happens, they climb onto the host and seek a site  
for attachment.
PREVENTION
1. Use repellent that contains 20 percent or more DEET, 
picaridin, or IR3535 on exposed skin for protection 
that lasts several hours. Use products that contain 
permethrin on clothing. Treat clothing and gear, 
such as boots, pants, socks and tents with products 
containing 0.5% permethrin. Additional repellent 
options are available. For more information, see 
http://cfpub.epa.gov/oppref/insect/.
2. Treat dogs and cats for ticks as recommended by a 
veterinarian.
3. Check for ticks daily, especially under the arms, in 
and around the ears, inside the belly button, behind 
the knees, between the legs, around the waist, and 
on the hairline and scalp.
4. Shower soon after being outdoors.
5. For tips on “tick-safe” landscaping, see  
www.cdc.gov/lyme/prev/in_the_yard.html.
TICK REMOVAL
1. Use fine-tipped tweezers to grasp the tick as close to the skin’s 
surface as possible. You may use specialized tick removal tools, 
if you already have them. The key is to remove the tick as soon 
as possible. Avoid folklore remedies such as using nail polish, 
petroleum jelly, or heat to make the tick detach from the skin.
2. Pull upward with steady, even pressure. Don’t twist or jerk the 
tick; this can cause the mouth-parts to break off and remain in 
the skin. If this happens, remove the mouth-parts with clean 
tweezers. If you are unable to remove the mouth parts easily, 
leave them alone and let the skin heal. 
3. After removing the tick, thoroughly clean the bite area and your 
hands with rubbing alcohol, an iodine scrub, or soap and water.
Embedded 
tick
TICK BITE PROPHYLAXIS 
The Infectious Disease Society of America (IDSA) does not generally recommend antimicrobial prophylaxis for prevention 
of Lyme disease after a recognized tick bite. However, in areas that are highly endemic for Lyme disease, a single dose of 
doxycycline may be offered to adult patients (200 mg) who are not pregnant and to children older than 8 years of age  
(4 mg/kg up to a maximum dose of 200 mg) when all of the following circumstances exist:
a. Doxycycline is not contraindicated.
b. The attached tick can be  identified as an adult or nymphal I. scapularis tick. 
c. The estimated time of attachment is ≥36 h based on the degree of engorgement of the tick with blood or likely time of 
exposure to the tick. 
d. Prophylaxis can be started within 72 h of tick removal. 
e. Lyme disease is common in the county or state where the patient lives or has recently traveled, (i.e., CT, DE, MA, MD, 
ME, MN, NH, NJ, NY, PA, RI, VA, VT, WI).
Antibiotic treatment following a tick bite is not recommended as a means to prevent anaplasmosis, babesiosis, 
ehrlichiosis, or Rocky Mountain spotted fever. There is no evidence this practice is effective, and it may simply delay 
onset of disease. Instead, persons who experience a tick bite should be alert for symptoms suggestive of tickborne illness 
and consult a physician if fever, rash, or other symptoms of concern develop. 
Tularemia prophylaxis is recommended only in cases of laboratory exposure to infectious materials: 
• Doxycycline (100 mg orally BID X 14 days) is generally recommended for prophylaxis in adults. 
• Ciprofloxacin (500 mg orally BID) is not FDA-approved for prophylaxis of tularemia but has demonstrated efficacy in 
various studies, and may be an alternative for patients unable to take doxycycline.
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For more information please contact:
Centers for Disease Control and Prevention
Division of Vector-Borne Diseases
3156 Rampart Road, Fort Collins, CO 80521
Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-63548
Contact: www.cdc.gov/cdc-info/
Web: www.cdc.gov/ticks
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